Analysis of YMDD Mutants in Hepatitis B Virus Infected Patients with Lamivudine Therapy by Restriction Fragment Length Polymorphism (RFLP) of the PCR Products

杨丹红,梁伟峰,赵年丰,范骏,谢远军,潘小平,陈智

DOI: https://doi.org/10.3760/j:issn:0254-5101.2002.04.035

2002-01-01

Abstract:Objective To analyze the emergence of YMDD variants in patients with hepatitis B treated with lamivudine. Methods The aminoacid substitution from methionine or isoleucine at the YMDD(tyrosine, methionine, aspartate, aspartate) motif at the HBV polymerase gene is main mutation responsible for resistant to lamivudine treatment. Generated from a fragment of domain C of the polymerase gene from clinical samples that patients' HBV DNA became positive again and they were negative even during lamivudine therapy. Variants were detected by cleavage of the products of the three PCRs with following enzymes: FokⅠ, SspⅠ, Alw441. The results of PCR-RFLP were analysed by 8.4% polypropylene acidemide gel electrophoresis. The PCR-RFLP assay were compared to direct sequencing. Results There were 33 patients' HBV DNA became positive again and two patients' HBV DNA have been positive for one year. The YMDD variants were detected in 14 of 35 serum samples with 4 cases YIDD variant 6 cases YVDD variant and 1 case YI/MDD in concordance with direct sequening. The other 3 patients' samples showed YI/VDD mutations, which compare to the direct sequence and were concordant with direct sequening too. The PCR-RFLP assay of the mixed sera of YIDD and YVDD variants are the same as that of the serum of YI/VDD variant. Conclusion The PCR-RFLP is suitable for fast detection of YMDD variants of viral polymerase in hepatitis B patients with lamivudine therapy.